Interchangeability of 3 recombinant anti-HBV vaccines in primary schedule, irrespective of dose and HBsAg subtype: the first prospective, open-label, randomized study in healthy adult population.
Weronika
W
Rymer
Małgorzata
M
Zalewska
Aleksandra
A
Szymczak
Anna
A
Zubkiewicz-Zarębska
Brygida
B
Knysz
D000328:Adult; D005260:Female; D006509:Hepatitis B / Q000378:metabolism / Q000517:prevention & control*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011897:Random Allocation; D016896:Treatment Outcome; D014614:Vaccines, Synthetic
D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic